Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Status:
Unknown status
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This research focuses on women with breast cancer whose disease has not significantly
progressed, but who have 5 or more lymph nodes involved. In this study subjects will receive
bevacizumab, a drug which is FDA approved for colon cancer but not for breast cancer, in
combination with a regimen of approved chemotherapy drugs known as "dose dense chemotherapy."
The study will observe the effectiveness and tolerability of this regimen.